<DOC>
	<DOCNO>NCT00738868</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , cetuximab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Radiation therapy use high-energy x-ray kill tumor cell . Stereotactic radiation therapy may able send x-ray directly tumor cause less damage normal tissue . Giving cetuximab together stereotactic radiation therapy may kill tumor cell . PURPOSE : This phase II trial study give cetuximab together stereotactic radiation therapy work treat patient recurrent squamous cell carcinoma head neck cancer remove surgery .</brief_summary>
	<brief_title>Cetuximab Stereotactic Radiation Therapy Treating Patients With Recurrent Head Neck Cancer That Can Be Removed By Surgery</brief_title>
	<detailed_description>OBJECTIVES : Primary - Evaluate local control 12 month patient recurrent squamous cell carcinoma head neck treat cetuximab stereotactic radiotherapy . Secondary - Determine incidence cutaneous toxicity . - Assess care development skin reaction . - Determine quality life patient treated drug . - Determine tumor response 2 month . OUTLINE : This multicenter study . Patients receive cetuximab IV weekly 5 week . Patients undergo stereotactic radiotherapy 3 time weekly week 2 3 . After completion study therapy , patient follow 2 month every 3 month 2 year .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm squamous cell carcinoma head neck Unresectable disease Recurrent disease No metastatic disease Disease previously irradiate area must prove biopsy image At least 3 month prior radiotherapy diagnosis recurrent disease Surgery brachytherapy must possible Measurable evaluable disease RECIST criteria No available curative therapy PATIENT CHARACTERISTICS : Karnofsky performance status 60100 % Not pregnant nursing No psychological , familial , social , geographical reason would make monitoring patient impossible No malignant disease PRIOR CONCURRENT THERAPY : See Disease Characteristics No concurrent participation another clinical study experimental drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>recurrent squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage III squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage III squamous cell carcinoma larynx</keyword>
	<keyword>stage III verrucous carcinoma larynx</keyword>
	<keyword>recurrent squamous cell carcinoma larynx</keyword>
	<keyword>recurrent verrucous carcinoma larynx</keyword>
	<keyword>recurrent squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage III squamous cell carcinoma lip oral cavity</keyword>
	<keyword>recurrent verrucous carcinoma oral cavity</keyword>
	<keyword>stage III verrucous carcinoma oral cavity</keyword>
	<keyword>recurrent squamous cell carcinoma nasopharynx</keyword>
	<keyword>stage III squamous cell carcinoma nasopharynx</keyword>
	<keyword>recurrent squamous cell carcinoma oropharynx</keyword>
	<keyword>stage III squamous cell carcinoma oropharynx</keyword>
	<keyword>recurrent squamous cell carcinoma paranasal sinus nasal cavity</keyword>
	<keyword>stage III squamous cell carcinoma paranasal sinus nasal cavity</keyword>
	<keyword>recurrent salivary gland cancer</keyword>
	<keyword>salivary gland squamous cell carcinoma</keyword>
	<keyword>stage III salivary gland cancer</keyword>
</DOC>